Cerebral Autoregulation and Vasospasm in Patients With TBI

January 26, 2022 updated by: Deborah Stein, University of Maryland, Baltimore

Cerebral Autoregulation and Vasospasm in Patients With Traumatic Brain Injury

Traumatic brain injury (TBI) affects 1.5 million patients per year in the United States, resulting in more than 50,000 deaths and more than 230,000 hospitalizations annually. Approximately 90,000 of these patients will suffer permanent impairment and more than half will experience short-term disability.

Secondary injury processes play a critical role in the development of ischemia after trauma to the central nervous system and occur hours-to-days after the primary insult. Ischemia can lead to cerebral infarction or stroke. Ischemia has been described as the single most important secondary insult and has been identified histologically in approximately 90% of patients who die following closed head injury. Several factors resulting in post-traumatic cerebral ischemia have been identified: increased intracranial pressure (ICP), systemic arterial hypotension, and cerebral vasospasm. Cerebral vasospasm has been described as a sustained arterial narrowing. Clinically, the onset of new or worsening neurological symptoms is the most reliable indicator of cerebral vasospasm following a ruptured cerebral aneurysm. However, cerebral vasospasm is often unrecognized in patients suffering from moderate to severe TBI. These patients frequently have altered mental status due to the primary brain injury. In addition, they require narcotics for their pain and paralytics and/or sedatives while on a mechanical ventilator for airway protection. Thus, relying on the neurological exam to observe deteriorating neurological signs consistent with post-traumatic vasospasm (PTV) is reliable. While the etiology and outcome of patients with vasospasm secondary to ruptured aneurysm is well documented, the clinical significance of PTV after TBI is unknown. A better understanding of the role of cerebral autoregulation in the development of cerebral vasospasm could provide the answer. This proposal is for a pilot observational study describing the association of the impairment of cerebral autoregulation as measured by near infrared spectroscopy (NIRS) with the development of clinically significant vasospasm in patients with moderate to severe TBI. The information will serve as preliminary data for further study.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

Primary Objectives: 1. To determine if impaired cerebral autoregulation as measured by NIRS is associated with clinically significant vasospasm in patients with moderate to severe TBI; 2. To determine the sensitivity and specificity of NIRS in detecting clinically significant vasospasm with Transcranial Doppler (TCD) ultrasound followed by CT brain angiography and diffusion-weighted brain MRI as the gold standard . Secondary Objectives: 1. To determine the relationship between impaired cerebral autoregulation and outcomes; 2. To determine the relationship between impaired cerebral autoregulation, clinically significant vasospasm and outcomes

Clinical observations The subject will be continuously monitored with INVOS NIRS system within the first 24 hours after admission up to 7 days while the subject is still in the STC. If decreased cerebral oxygenation is detected by NIRS, TCDs will be offered to the family and considered part of routine clinical care. If vasospasm is detected by TCD, CT brain angiography will be offered to the family for angiographic confirmation and considered part of routine clinical care. If vasospasm is confirmed by CT brain angiography, diffusion-weighted MRI will be offered to the family to evaluate for cerebral ischemia/infarction and considered part of routine clinical care.

Laboratory evaluations All patients will have at least twice daily measurements of serum electrolytes, blood counts, arterial blood gases, and coagulation profile as per our standard of care. Culture results will be recorded. No tests or procedure will be ordered for research purposes only.

Patient Management All enrolled patients will be admitted to the Neurotrauma Critical Care Unit (NTCC) and be jointly managed by the Trauma, Critical Care and Neurosurgical services. All patients will be managed utilizing the STC Institutional Severe Traumatic Brain Injury Management Algorithm which is based on the Brain Trauma Foundation Guidelines for the Management of Severe Traumatic Brain Injury. Other consults will be obtained as clinically indicated.

Questionnaires / Assessment tools Functional outcome using the Extended Glasgow Outcome Scale (GOS-E) will be assessed in the STC Outpatient Clinic as part of their standard of care. An early functional outcome assessment will be obtained if the GOS-E form is completed at the STC Outpatient Clinic within 6 weeks post hospital discharge day. A mid functional outcome assessment will be obtained if the GOS-E form is completed at the STC Outpatient Clinic 6 weeks to 3 months post hospital discharge day. A late functional outcome assessment will be obtained if the GOS-E form is completed at the STC Outpatient Clinic 3 months to 6 months post hospital discharge day. Finally, a very late functional outcome assessment will be obtained if the GOS-E form is completed at the STC Outpatient Clinic more than 6 months post-hospital discharge day.

STATISTICAL CONSIDERATIONS / ANALYSIS OF DATA The goal of this pilot study is to determine if impaired cerebral autoregulation as measured by NIRS is associated with the development of clinically significant vasospasm in patients with moderate to severe TBI. By enrolling 100 patients in the study, it is expected to estimate the correlation to within 0.098 with a probability of at least 95%. In this study, all primary and secondary outcomes may be classified into two categories: binary and continuous. In the first step, quantitative descriptive statistics will be used initially to study the characteristics of patients and the association between clinical outcomes (e.g. vasospasm) and various demographic and clinicopathologic variables such as age, gender and injury severity scores. For binary data, chi-square and Fisher's exact tests will be used to identify differences. For continuous variables, t-tests and analysis of variance (ANOVA) will be used to determine the significant association. These univariate tests will be done at a significance level of 0.05. In addition to constructing 95% confidence interval for the correlation of impaired cerebral autoregulation as measured by NIRS and clinically significant vasospasm, the investigators will also explore potential risk factors associated with impaired cerebral autoregulation and impaired cerebral autoregulation associated with vasospasm. To this end, the correlation will be analyzed using the logistic regression model with various demographic and clinicopathologic variables as independent variables. The stepwise regression procedure will be used for identifying potential risk factors for the incidence of vasospasm. To evaluate the validity of NIRs as an assessment method of vasospasm, the investigators will measure the agreement between TCD and NIRS by using kappa statistics.

Study Type

Observational

Enrollment (Actual)

25

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Maryland
      • Baltimore, Maryland, United States, 21201
        • R Adams Cowley Shock Trauma Center, University of Maryland Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

15 years and older (ADULT, OLDER_ADULT, CHILD)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

All patients aged 15 years and older, presenting with a motor score of <6 and thought to have TBI due to a mechanism of injury, will undergo screening with head computed tomography (CT). Admission CT will be interpreted by an attending radiologist to determine Head Abbreviated Injury Score (AIS) score. If the AIS score by CT is > 2, the patient will be eligible for the study. Patients determined by neurosurgery to have a non-survivable TBI on admission will be excluded given the poor likelihood of completion of the study protocol.

Description

Inclusion Criteria:

  • 15 years of age and greater
  • Motor Glasgow Coma Score (GCS) < 6 within approximately 24 hours of admission
  • Head AIS > 2

Exclusion Criteria:

  • Motor GCS >5
  • Determination of non-survivability on admission
  • Non-English speakers
  • Prisoners that are on parole or probation
  • Active duty military
  • Pregnant patients

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Functional Outcome as assessed by the Glasgow Functional Outcome-Extended
Time Frame: within 12 months post hospital discharge
within 12 months post hospital discharge

Secondary Outcome Measures

Outcome Measure
Time Frame
Mortality
Time Frame: within 30 days
within 30 days
Hospital Length of Stay
Time Frame: within 60 days
within 60 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

November 1, 2015

Primary Completion (ACTUAL)

June 30, 2017

Study Completion (ACTUAL)

June 30, 2017

Study Registration Dates

First Submitted

January 19, 2015

First Submitted That Met QC Criteria

January 27, 2015

First Posted (ESTIMATE)

January 30, 2015

Study Record Updates

Last Update Posted (ACTUAL)

January 27, 2022

Last Update Submitted That Met QC Criteria

January 26, 2022

Last Verified

January 1, 2022

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cerebral Infarct

Clinical Trials on No intervention

3
Subscribe